Artelo Biosciences (ARTL) investor relations material

Corporate overview and strategy

• Focused on lipid signaling modulation with three main drug candidates targeting large, unmet medical needs in cancer anorexia, glaucoma, pain, and anxiety disorders.

• Two assets are in-licensed (from AstraZeneca and Stony Brook University), and one is proprietary.

• Robust patent estate with issued composition of matter patents in 22 countries for the co-crystal asset.

• Leadership team highlighted for deep industry experience and successful track record.

• Capitalization includes just under 5 million shares outstanding, over $4 million in cash, and no debt.

ART27.13 (Cancer Anorexia and Glaucoma)

• ART27.13 is a synthetic dual cannabinoid receptor agonist, peripherally selective, avoiding CNS side effects.

• Phase I showed two-thirds of patients stabilized or gained weight; phase II interim data showed 6% average weight gain at top dose, with improved physical activity and quality of life.

• No serious adverse events in phase I or II; well-tolerated up to 1,300 mcg.

• Glaucoma pilot phase II (DREAM trial) fully funded externally, results expected by year-end or early next year.

• Lower dose used in glaucoma trial to minimize risk of weight gain in elderly population.

ART26.12 (FABP5 Inhibitor for Pain and Inflammation)

• Targets fatty acid binding protein 5, with potential in pain, inflammation, and chemotherapy-induced peripheral neuropathy.

• Preclinical models showed positive results in pain reduction.

• Phase I completed with excellent safety profile; no drug-attributed toxicities in 55 subjects.

• Linear pharmacokinetics and wide therapeutic window demonstrated.

• Can be dosed in fed or fasted state, offering flexibility.